While some animal studies have shown promise, these results don't always translate to humans
Available from: J L Sievenpiper 1 2 3 , J Ard 4 , M Blher 5 , W Chen 6 , J B Dixon 7 , A Fitch 8 , L Gigliotti 9 , K Khunti 10 , A Lecube 11 12 , M E J Lean 13 , B Mittendorfer 14 , A F H Pfeiffer 15 , D H Ryan 16 , T Vilsbll 17 18 , L F Van Gaal 19
Final research-target dose 2.4 mg + 2.4 mg weekly Titration length ~16 weeks Trial duration 68 weeks (REDEFINE 1 / REDEFINE 2) Route Subcutaneous, once weekly Compound Delivery: 2.4 mg / 2.4 mg Maintenance Pre-blended vials simplify weekly administration to a single injection but lock the ratio at 1:1
ASHP Foundation
As an antioxidant, glutathione helps to reduce oxidative damage caused by free radicals, which can lead to fatigue
Every infusion is physician-formulated and lab-verified